Joint Fellowship Training Program Fellows Denali Dubravka Kufrin, Ph.D. Phone:   301-827-6575 E-Mail:   dubravka.kufrin@fda.hhs.gov Professional Background Dr. Kufrin received her M.S. and Ph.D. from the University of Zagreb, Croatia and completed her graduate work at The Children's Hospital of Philadelphia. Her post-doctoral training was at the Mouse Cancer Genetics Program at the National Cancer Institute in Frederick, Maryland. She began the NCI/FDA Oncology Product Research/Review Fellowship program in October 2006. Research Interests Dr. Kufrin's research interests include the mechanisms of leukemic transformation and gene cooperativity, as well as pathways of platelet activation, blood coagulation, and proteolysis cascades. The basis of her graduate work was expression of therapeutic proteins in platelets as a vehicle for transportation of pro-coagulation or pro-lytic proteins to the site of injury. She genetically expressed urokinase plasminogen activator in platelets of mice, whose physiologic characteristics closely mimic those of human patients with Quebec Platelet Disorder. Dr. Kufrin received a Merit Award in 2002 for her work from the American Society of Hematology. During her post-doctoral studies, she worked on development of mouse models of cancer; specifically, Notch induced leukemia and cooperativity of Notch-interacting genes. As NCI/FDA Fellow, she is working on safety issues associated with vaccine cell substrates and oncogenic risks associated with using current cell lines as substrates. Fellowship Experiences "The NCI-FDA Fellowship gives me the opportunity to explore regulatory and review processes that take place at FDA. The hands-on learning experience that I receive is invaluable. The opportunity to learn from FDA-sponsored training courses together with the laboratory and research activities based at the NIH campus broadened my understanding of the product review process and regulatory affairs." Career Goals "I wish to stay in regulatory affairs and focus on the daily challenges in the evaluation of safety and efficacy of new therapies for cancer and other diseases."

Home   |   Privacy Notice   |   Accessibility